Saturday 17 October 2026 Export ZJYL’s income statement to Excel — free account

Jin Medical International Ltd.

ZJYL Healthcare Medical Instruments & Supplies

Jin Medical International Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $20.7 million, down 12.0% from fiscal 2024.

2.08 0.08 −3.70%

Follow ZJYL

Alert me

Market cap: $340.9M
P/E: —
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: 3.66
Beneish M: −2.46
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 340.91

Revenue —

Net Income 4.60

Free Cash Flow (7.29)

Net Debt (27.24)

Current Ratio 1.95

Debt/Equity 0.10

P/E ratio —

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth (8.82%)

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	17	27	30	30
Receivables	8	9	6	6
Inventory	5	5	5	6
Other	—	—	—	1
	31	43	44	45

	2023	2024	2025	Q'26
Payables	3	3	3	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	9	17	24	23

Compound Annual Growth %

	10y	5y	3y
Sales	—	(0.07%)	2.54%
Cash Flow	—	3.01%	22.47%
Earnings	—	(15.14%)	(25.48%)
Book Value	—	16.08%	24.74%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	21
’24	—	—	—	—	24
’23	—	—	—	—	20
’22	—	—	—	—	19
’21	—	—	—	—	19
’21	—	—	—	—	21

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	3
’24	—	—	—	—	(1)
’23	—	—	—	—	3
’22	—	—	—	—	2
’21	—	—	—	—	6
’20	—	—	—	—	3

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	—	—	—	—
’25	1	—	(4)	—	(4)
’24	0	—	(1)	—	(2)
’23	3	—	3	—	3
’22	—	—	2	—	2
’21	—	—	—	—	6
’20	—	—	—	—	3

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0.18
’24	—	—	—	—	0.40
’23	—	—	—	—	0.40
’22	—	—	—	—	0.40
’21	—	—	—	—	0.33
’20	—	—	—	—	0.28

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	4.84	14.02	3.62	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	509.87	332.00	23.80
People
People	Employees	—	—	—	—	—	—	258	245	269	273
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.08	0.09	0.08
Income, $m
Income, $m	Revenue	—	—	—	20	16	19	19	20	24	21
	Gross margin, %	—	—	—	36.88	33.95	32.30	32.30	34.23	40.43	29.22
	EBT	—	—	—	4	2	3	(2)	3	4	2
	EBT margin, %	—	—	—	20.26	14.53	14.29	0.00	16.25	17.80	7.71
	Net income	—	—	—	4	2	0	0	3	3	1
	Depreciation	—	—	—	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	2.55	2.02	0.00	2.84	2.73	3.00	2.64
	Earnings	—	—	—	0.46	0.28	0.33	0.40	0.40	0.40	0.18
	Cash flow	—	—	—	(0.17)	0.31	0.73	0.23	0.43	(0.15)	0.37
	Capex	—	—	—	0.00	0.00	0.00	(0.01)	(0.01)	(0.14)	(0.85)
	Free cash flow	—	—	—	(0.17)	0.31	0.73	0.23	0.41	(0.30)	(0.48)
	Book value	—	—	—	1.34	1.35	0.00	2.26	3.30	3.65	3.78
	Shares, m	—	—	—	8	8	8	7	7	8	8
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/B	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/FCF	—	—	—	0.00	0.00	0.00	0.00	0.00	(6.19)	6.44
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(1)	3	6	2	3	(1)	3
	Capex	—	—	—	0	0	0	0	0	(1)	(7)
	Free cash flow	—	—	—	(1)	3	6	2	3	(2)	(4)
Balance, $m
Balance, $m	Working capital	—	—	—	8	8	13	8	22	26	20
	Total debt	—	—	—	3	3	—	—	—	—	—
	Net debt	—	—	—	0	0	(7)	(7)	(17)	(27)	(30)
	Shareholders’ equity	—	—	—	11	11	15	15	24	29	30
Returns, %
Returns, %	ROA	—	—	—	0.00	10.71	12.64	27.49	10.69	9.34	2.40
	ROIC	—	—	—	0.00	0.00	30.79	0.00	24.61	126.69	0.00
	ROE	—	—	—	0.00	20.51	19.03	0.00	14.68	14.00	4.10

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AVR Anteris Technologies Global Corp.	$619.8M	— (loss-making)	—	+63.27% (above 0%: growing)	n/m	−6.84% (below 0%: shrinking)	76.91%	(3,072.05%)	Compare
ANGO AngioDynamics, Inc.	$487.0M	— (loss-making)	— (loss-making)	+6.87% (above 0%: growing)	n/m	+5.62% (above 0%: growing)	59.37%	(9.02%)	Compare
NNNN Anbio Biotechnology	$474.8M	—	—	—	—	—	—	—	Compare
EMBC Embecta Corp.	$365.5M	4.2×	3.8×	−8.05% (below 0%: shrinking)	−53.85% (below 0%: shrinking)	−49.63% (below 0%: shrinking)	56.42%	17.92%	Compare
ZJYL Jin Medical International Ltd.	$340.9M	—	—	—	—	−8,074.17% (below 0%: shrinking)	34.44%	0.00%
SMTI Sanara MedTech Inc.	$322.4M	— (loss-making)	125×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%	Compare
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%	Compare
Median of peers	$343.9M	13.8×	26.1×	+6.87%	−10.64%	−6.84%	56.42%	17.29%

All 55 Medical Instruments & Supplies stocks →

Jin Medical International Ltd. (ZJYL) key facts

Concern: Jin Medical International Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $20.7 million, down 12.0% from fiscal 2024.
Jin Medical International Ltd. (ZJYL) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ZJYL traded at $2.08, a market capitalization of $340.9 million.
Return on equity was 4.10% and debt-to-equity 0.10.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 3.66 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.